Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any 3-M syndrome in which the cause of the disease is a mutation in the CUL7 gene.
Features include always present findings: Intrauterine growth retardation and Growth delay; and common findings: Long philtrum, Excessive inward curvature of the lower spine (hyperlordosis), Pointed chin, and Triangular face. 37 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 6 | Joint dislocation, Excessive inward curvature of the lower spine (hyperlordosis), Delayed skeletal maturation |
Growth and development | 4 | Short stature, Postnatal growth retardation, Intrauterine growth retardation |
Head and neck | 3 | Thick lower lip vermilion, Mandibular prognathia, Triangular face |
Brain and nerves | 2 | Intellectual disability, Depressed nasal bridge |
Arms and legs | 2 | Clinodactyly of the 5th finger, Short 5th finger |
Lungs and breathing | 1 | Neonatal respiratory distress |
Pregnancy and birth | 1 | Neonatal respiratory distress |
Age of onset: at birth.
Neonatal period. Some children with 3-M syndrome present in the neonatal period with feeding difficulties requiring early feeding support . A small proportion of infants suffer from significant respiratory distress and/or recurrent respiratory tract infections in early life that can be life threatening . This is more common in the Yakut population, in which 41% of affected infants had asphyxia and respiratory distress at birth and 25.6% required mechanical ventilation . Growth deficiency. The most striking feature of 3-M syndrome is severe intrauterine growth restriction. Birth length is 40-42 cm, whereas the head size is normal for gestational age.
Source: GeneReviews — "3-M Syndrome"
CUL7 encodes cullin 7 (1,698 aa). Core component of the 3M and Cul7-RING(FBXW8) complexes, which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. Highest expression in Pituitary (73.3 TPM) and Cervix Endocervix (52.0 TPM).
3M syndrome 1 is associated with mutations in the CUL7 gene on chromosome 6.
The CUL7 protein participates in AcM-UBE2M transfers NEDD8 to CUL9:RBX1 and Expression of Cullin-7 pathways.
CUL7 is classified as a druggable target (Kinase category) with score 0.0.
The CUL7 founder pathogenic variant reported in the Yakut population, , may be associated with an increased risk of respiratory distress in the neonatal period. reported 41.9% of children homozygous for this variant presented with asphyxia and respiratory distress at birth, and 25.6% of these children required mechanical ventilation.
Source: GeneReviews — "3-M Syndrome"
No consensus clinical diagnostic criteria for 3-M syndrome have been published.
3-M syndrome should be suspected in a proband with a combination of the following clinical, radiographic, and family history features.
Clinical features
Source: GeneReviews — "3-M Syndrome"
Intrauterine growth restriction is a nonspecific finding that occurs in approximately 0.17% of all live-born children. 3-M syndrome must be distinguished from other genetic and acquired intrauterine growth restriction-malformation syndromes. Table 2. Disorders of Known Genetic Cause to Consider in the Differential Diagnosis of 3-M Syndrome
Gene(s) | Disorder | MOI | Clinical Features of Disorder |
|---|---|---|---|
Overlapping w/3-M syndrome | Distinguishing from 3-M syndrome Genetically heterogeneous1 | Silver-Russell syndrome (SRS) | See footnote 2. |
TRIM37 | Mulibrey nanism (OMIM 253250) | AR | IUGR |
IGF1R | IGF1R deficiency (OMIM 270450) |
Genetic testing for CUL7 is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for 3M syndrome 1. The disease remains an area of unmet medical need.
No clinical practice guidelines for 3-M syndrome have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease in an individual diagnosed with 3-M syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
3-M Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Physical exam to assess for joint hypermobility, kyphoscoliosis, hip dysplasia/dislocation | • Hip US in infancy or hip radiographs in older children may be helpful.
Refer to orthopedist if hip dysplasia/dislocation or scoliosis is identified.
| Physical exam to assess for hypospadias |
Refer to pediatric endocrinologist to assess for:
Gonadal function in pubertal males by physical exam serum concentrations of FSH, LH, testosterone;
GH deficiency /or GH insensitivity.
|
| By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of 3-M syndrome to facilitate medical personal decision making
FSH = follicle-stimulating hormone; GH = growth hormone; LH = luteinizing hormone; MOI = mode of inheritance; US = ultrasound
Source: GeneReviews — "3-M Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "3-M Syndrome"
View trials for 3M syndrome 1
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 5.
3-M Syndrome: Recommended Surveillance
System/Concern | Evaluation | Frequency
| Monitor growth on standard growth charts w/special attention to growth velocity. | Every 6-12 mos
| • Assess for joint hypermobility.
Examine back for kyphoscoliosis.
| Annually
Assess for hip dislocation. | At each visit in infancy, esp if walking is delayed
| Echocardiogram w/measurement of aortic root | Consider in adolescence
Source: GeneReviews — "3-M Syndrome"
Phenotype severity distribution: 2 always present features, 4 common features.
No clinical trials have been registered for 3M syndrome 1.
10 publications have been identified in PubMed for 3M syndrome 1. Research spans Review / Meta-Analysis (44%), Case Report / Case Series (33%), and Basic Science / Preclinical (22%).
Fakeeha JH (2026). [PMID: 41836891](https://pubmed.ncbi.nlm.nih.gov/41836891/). *J Surg Case Rep*. [Case Report / Case Series]
Chen XL (2025). [PMID: 41059455](https://pubmed.ncbi.nlm.nih.gov/41059455/). *Appl Clin Genet*. [Review / Meta-Analysis]
Alhuthil R (2025). [PMID: 41306440](https://pubmed.ncbi.nlm.nih.gov/41306440/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]
Bacchi I (2025). [PMID: 41437277](https://pubmed.ncbi.nlm.nih.gov/41437277/). *Ital J Pediatr*. [Review / Meta-Analysis]
Zhang L (2025). [PMID: 40372227](https://pubmed.ncbi.nlm.nih.gov/40372227/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Review / Meta-Analysis]
Liu H (2025). [PMID: 41234413](https://pubmed.ncbi.nlm.nih.gov/41234413/). *Front Pediatr*. [Case Report / Case Series]
Piao Y (2024). [PMID: 38407006](https://pubmed.ncbi.nlm.nih.gov/38407006/). *J Clin Res Pediatr Endocrinol*. [Case Report / Case Series]
Zaka A (2024). [PMID: 37345548](https://pubmed.ncbi.nlm.nih.gov/37345548/). *J Biomol Struct Dyn*. [Basic Science / Preclinical]
Akalın A (2024). [PMID: 39643721](https://pubmed.ncbi.nlm.nih.gov/39643721/). *Eur J Pediatr*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 4:29 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
IUGR postnatal growth deficiency |
Source: GeneReviews — "3-M Syndrome"
AI-curated news mentioning 3M syndrome 1
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.